MEDICINA
Departamento
Dalhousie University
Halifax, CanadáPublicaciones en colaboración con investigadores/as de Dalhousie University (16)
2022
-
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma
Blood, Vol. 140, Núm. 21, pp. 2248-2260
2020
-
As COVID-19 cases, deaths and fatality rates surge in Italy, underlying causes require investigation
Journal of Infection in Developing Countries, Vol. 14, Núm. 3, pp. 265-267
-
COVID-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction
Cardiovascular research, Vol. 116, Núm. 10, pp. e132-e133
-
Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection
Journal of Infection
-
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
The Lancet, Vol. 396, Núm. 10262, pp. 1563-1573
-
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
The Lancet Haematology, Vol. 7, Núm. 5, pp. e370-e380
-
Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19
Critical Care, Vol. 24, Núm. 1
2019
2017
-
Genetic association study of exfoliation syndrome identifies a protective rare variant at LOXL1 and five new susceptibility loci
Nature Genetics, Vol. 49, Núm. 7, pp. 993-1004
-
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
The Lancet Oncology, Vol. 18, Núm. 2, pp. 241-250
2016
-
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial
The Lancet, Vol. 387, Núm. 10027, pp. 1551-1560
-
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
The Lancet Oncology, Vol. 17, Núm. 8, pp. e328-e346
2015
-
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051
-
Elotuzumab therapy for relapsed or refractory multiple myeloma
New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631
2010
-
Quality, quantity and harmony: The DataSHaPER approach to integrating data across bioclinical studies
International Journal of Epidemiology, Vol. 39, Núm. 5, pp. 1383-1393
2009
-
International Myeloma Working Group molecular classification of multiple myeloma: Spotlight review
Leukemia, Vol. 23, Núm. 12, pp. 2210-2221